Treatment-Resistant Depression

  • ID: 2222123
  • March 2013
  • 228 Pages
  • John Wiley and Sons Ltd
1 of 4

Successful management of patients with treatment–resistant depression is going to require a thorough understanding of the biological basis for both the depression and its failure to respond to standard treatments. This book clearly and succinctly summarizes the latest  scientific research and its applications in clinical practice. 

 A first step is a clear definition of what constitutes treatment–resistant depression so that clinical trials and other studies are using common criteria, enabling comparison and meta–analysis of their outcomes.  The opening chapter reviews definitions and predictors of originating from different fields and discusses their usefulness in clinical practice and clinical research.  The next chapter proposes a new definition, adapting terminology from medicine. 

Biological classification requires identification of genetic risk factors: with gene variants accounting for 50% of the variance in the clinical outcomes of antidepressant treatments this is clearly a fruitful area of research.  Chapter 3 describes several genes already associated with treatment–resistant depression and, while further READ MORE >

Note: Product cover images may vary from those shown
2 of 4

List of Contributors vii

Foreword ix

1 Definitions and Predictors of Treatment–resistant Depression 1
Daniel Souery and William Pitchot

2 Treatment–resistant Depression: A Separate Disorder A New Approach 21
Hans–Jürgen Möller, Florian Seemüller, Rebecca Schennach and Ramesh K. Gupta

3 Genetics of Treatment–resistant Depression 43
Chiara Fabbri, Stefano Porcelli and Alessandro Serretti

4 Is There a Role for Switching Antidepressants in Treatment–resistant Depression? 91
Stuart Montgomery

5 The Role of Atypical Antipsychotics in Inadequateresponse and Treatment–resistant Depression 107
Siegfried Kasper and Elena Akimova

6 Lithium, Thyroid Hormones and Further Augmentation Strategies in Treatment–resistant Depression 129
Robert Haußmann and Michael Bauer

7 The Role of Nonpharmacological Interventions in Treatment–resistant Depression 159
Thomas E. Schläpfer and Sarah Kayser

8 The Role of Psychotherapy in the Management of Treatment–resistant Depression 183
Michael E. Thase

Index 209

Note: Product cover images may vary from those shown
3 of 4

After all, this book is recommended for the young psychiatrist, who wants to read an easy introduction to the fascinating world of treatment of resistant depression.   (Acta Psychiatrica Scandinavica, 9 November 2013)

This is a monograph, which could be of great interest to psychiatrists managing patients with TRD. The chapters are written clearly, and the references are comprehensive and up–to–date.   (Human Psychopharmacology: Clinical & Experimental, 6 November 2013)

The editors should be congratulated for accomplishing the amazing feat of presenting so much information in such a compact book. With an investment of just a few hours, readers can be updated on a very complicated subject . . . The editors should be commended on detailing a variety of treatment options, including nonpharmacological options, which other books fail to emphasize.   (Doody s, 23 August 2013)

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown




Our Clients

  • Amneal Pharmaceuticals LLC.
  • Amgen Inc.
  • LEO Laboratories Ltd.
  • Pfizer Inc.
  • Roche Diagnostics Ltd.
  • Merck & Co., Inc.
  • Sanofi S.A.